ESTRO 2023 - Abstract Book

S790

Monday 15 May 2023

ESTRO 2023

Figure 2. Dose distributions highlighting the different planning approaches in two example centres for the three benchmark cases. Conclusion From this first STOPSTORM.eu multi-center/multi-platform treatment planning benchmark study we obtained important information concerning current clinical practise from major European centres performing STereotactic Arrhythmia Radioablation for VT. With the strongly varying approaches of the centres as basis, the key task for the STOPSTORM.eu project is to find consensus, aiming to harmonize and optimize STAR practise in Europe. OC-0942 Geometric stability during Stereotactic Arrhythmia Radiotherapy R. de Jong 1 , N. van Wieringen 1 , M. van Ree 2 , E. Dieleman 1 , P.G. Postema 2 , J. Visser 3 , B. Balgobind 1 1 Amsterdam UMC, Radiation Oncology, Amsterdam, The Netherlands; 2 Amsterdam UMC, Cardiology, Amsterdam, The Netherlands; 3 Amsterdam, Radiation Oncology, Amsterdam, The Netherlands Purpose or Objective Patients with therapy-refractory ventricular tachycardia were enrolled in the STARNL-1 trial to receive non-invasive stereotactic arrhythmia radiotherapy with a single high dose fraction. As these patients are in a poor condition, target volumes may show excessive instability. Hence, we retrospectively quantified the geometric stability of the target volumes to assess our imaging and correction strategies. Materials and Methods Between December 2020 and October 2021 7 patients were enrolled, 6 in STARNL-1 trial, 1 compassionate use. The Internal target volume (ITV) was defined as the pro-arrhythmic ventricular region with correction for breathing motion using a 4DCT scan. All patients were male. PTV margin around the ITV was 5 mm. PTV volumes were on average 216 cm3 (range 93-300 cm3). A single fraction dose of 25 Gy was prescribed to the PTV. For all patients a 10 MV FFF 3 arc VMAT plan was designed. Image guidance was performed using online CBCT, matching on the target volume, correcting translational errors only. A correction is always evaluated using a verification CBCT scan with a 3 mm action level in vector length for the residual error. As this procedure resulted in a total of 7 CBCT scans for patient 1, the IGRT procedure was expanded to an online No Action Level (NAL) imaging procedure (4 CBCT scans pretreatment) for patient 2 to 7 (3 times CBCT scan calculating average displacement, followed by a table correction). Additionally, a practice run with only CBCT imaging was introduced 1 day before treatment assuring patient compliance and adequate treatment delivery with respect to stability of the patient and target volume. For all patients a post treatment CBCT scan was acquired. This resulted in a total of 67 CBCT scans for analysis. The CBCT match results are corrected for table shifts executed after previous CBCT scans. To report the stability of the target the standard deviation (SD) of the processed match results for all fractions was calculated. On-table times were all below 50 minutes. Beam-on times were on average 276 seconds with a maximum of 313 seconds. Results For patient 1 a total of 6 pre- and mid-treatment CBCT scans were needed to concur with the 3 mm vector length residual motion threshold before start of treatment and in between arcs . For patient 2-7 for all fractions the residual vector length was below the set threshold of 3 mm. The mean standard deviation was 0.11 cm (LR), 0.19 cm (CC), 0.12 cm (AP). The range of standard deviations was 0.03–0.35 cm (LR), 0.03–0.39 cm (CC), 0.04–0.28 cm(AP). Figure 1 shows results per patient.